Leppänen, J., Lindholm, V., Isohookana, J., Haapasaari, K., Karihtala, P., Lehenkari, P., Saarnio, J., Kauppila, J., Karttunen, T., Helminen, O., Huhta, H. (2019) Tenascin C, Fibronectin, and Tumor-Stroma Ratio in Pancreatic Ductal Adenocarcinoma. Pancreas, 48 (1), 43-48. doi:10.1097/MPA.0000000000001195
Tenascin C, fibronectin, and tumor-stroma ratio in pancreatic ductal adenocarcinoma
|Author:||Leppänen, Joni1; Lindholm, Ville1; Isohookana, Joel1;|
1Cancer and Translational Medicine Research Unit, Medical Research Center Oulu, University of Oulu and Oulu University Hospital, Oulu, Finland
2Upper Gastrointestinal Surgery, Department of Molecular Medicine and Surgery, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden
|Online Access:||PDF Full Text (PDF, 0.4 MB)|
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe202003067604
|Publish Date:|| 2020-03-06
Objectives: Pancreatic ductal adenocarcinoma (PDAC) is characterized by abundant stroma with increased expression of tenascin C and fibronectin. Their role and tumor-stroma ratio in PDAC are not well known. The aim of this study was to evaluate tenascin C and fibronectin expression and tumor-stroma ratio and their prognostic relevance in PDAC.
Methods: Ninety-five resected PDACs were immunohistochemically stained for tenascin C and fibronectin, and the expression was separately assessed in tumor bulk and front. Tumor-stroma ratio was determined with sections stained with hematoxylin-eosin.
Results: Tenascin C and fibronectin were abundantly expressed in the stroma of PDAC, but absent in adjacent normal pancreatic tissue. Fibronectin expression of the bulk was associated with high T class (P = 0.045). In the main analysis, tenascin C and fibronectin expression and tumor-stroma ratio were not associated with patient survival. In a subgroup analysis of early-stage PDAC (T1–T2 tumors), high tenascin C expression in the tumor bulk was associated with poor prognosis (hazard ratio, 8.23; 95% confidence interval, 2.71–24.96).
Conclusions: Tenascin C and fibronectin are abundantly expressed in PDAC, but they seem to have no major association with patient survival. However, in early-stage PDAC, tenascin C expression of the tumor bulk may have prognostic impact. Tumor-stroma ratio has no prognostic value in PDAC.
|Pages:||43 - 48|
|Type of Publication:||
A1 Journal article – refereed
|Field of Science:||
This work was supported by grants from the Orion Research Foundation (J.H.K.), ThelmaMäkikyrö Foundation (J.H.K., H.H.), Päivikki and Sakari Sohlberg Foundation (J.L., H.H.), Georg C. and Mary Ehrnroot Foundation (J.H.K., H.H.), Sigrid Juselius Foundation (J.H.K.), Finnish Medical Foundation (J.L., H.H.), Emil Aaltonen Foundation (J.L.), and Finnish Cultural Foundation (J.L.).
© 2018 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.